Olive allergens under the microscope: Ole e 7 and Ole e 9 sensitization does not increase symptom severity or adverse reactions to subcutaneous allergen immunotherapy
In brief
Minor olive allergen sensitization did not worsen immunotherapy reactions in 196 patients
In this retrospective study, 76% of 196 patients improved after one year of olive pollen immunotherapy, with six late local reactions and one severe systemic reaction reported. Sensitization to minor olive allergens was not linked to treatment tolerance or clinical response, but the findings reflect routine-care outcomes over one year, not a controlled comparison.
- Journal
- The World Allergy Organization journal (Q1)
- Published
- 4 November 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Manuel Alcántara Villar, Alicia López Guerrero, Miriam Bermúdez Bejarano, Cristina Ruiz González, Patricia de Manueles Tabliega, Guillermo Salamanca Fernández
- PMID
- 43022405
- DOI
- 10.1016/j.waojou.2026.101482
Why clinicians should know about it
- Picked for Immunology and Allergy (paper of the day, 16 November 2026): Clinical outcomes and safety of olive pollen immunotherapy
Abstract
BACKGROUND: In regions with prolonged and intense exposure to olive pollen, sensitization to minor allergens such as Ole e 7 and Ole e 9 and their specific IgE levels tend to increase. This has raised concerns regarding a potentially higher risk of adverse reactions during allergen immunotherapy. OBJECTIVE: To assess subcutaneous immunotherapy (SCIT) safety and the clinical outcomes observed after 1 year of treatment in routine clinical practice in patients with olive pollen-induced allergic respiratory disease, according to their molecular sensitization profiles. METHODS: This retrospective observational study included patients with rhinitis and/or asthma caused by olive pollen sensitization who received SCIT with a depigmented, polymerized olive pollen extract. Olive allergen sensitization profiles were determined using component-resolved diagnosis, and their association with disease severity, treatment tolerance, and clinical response was assessed. RESULTS: A total of 196 patients were included in the analysis. Rhinitis was present in 97% of patients and asthma in 94%, predominantly of moderate persistent severity. Sensitization to Ole e 1 was observed in 96% of patients, whereas 73% and 68% were sensitized to Ole e 7 and Ole e 9, respectively; 58% were sensitized to all 3 components. Six late local reactions and 1 grade 3 systemic reaction (EAACI classification) were reported. Clinical improvement according to the predefined clinical response criteria was observed in 76% of patients, along with a reduction in rescue medication use and a decrease in the number of patients requiring emergency department visits, from 60 at baseline to none after 1 year of follow-up. No association was observed between molecular sensitization profiles and SCIT tolerability or clinical response. CONCLUSION: SCIT with a depigmented polymerized olive pollen extract was well tolerated and was associated with favorable one-year clinical outcomes in a population with high environmental exposure to olive pollen, irrespective of sensitization to minor olive allergens.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.